-
Views
-
Cite
Cite
D. M. Gordon, T. W. McGovern, U. Krzych, J. C. Cohen, I. Schneider, R. LaChance, D. G. Heppner, G. Yuan, M. Hollingdale, M. Slaoui, P. Hauser, P. Voet, J. C. Sadoff, W. R. Ballou, Safety, Immunogenicity, and Efficacy of a Recombinantly Produced Plasmodium falciparum Circumsporozoite Protein-Hepatitis B Surface Antigen Subunit Vaccine, The Journal of Infectious Diseases, Volume 171, Issue 6, June 1995, Pages 1576–1585, https://doi.org/10.1093/infdis/171.6.1576
- Share Icon Share
Abstract
Twenty malaria-naive volunteers received a recombinant Plasmodium falciparum malaria vaccine (RTS,S) containing 19 NANP repeats and the carboxy terminus (amino acids 210–398) of the circum sporozoite (CS) antigen coexpressed in yeast with hepatitis B surface antigen. Ten received vaccine adjuvanted with alum, and 10 received vaccine adjuvanted with alum plus 3-deacylated monophosphoryl lipid A (MPL). Both formulations were well tolerated and immunogenic. MPL enhanced CS antibody levels (measured by ELISA, immunofluorescence, and inhibition of sporozoite invasion assays). After sporozoite challenge, 6 of 6 in the alum group and 6 of 8 in the alum-MPL group developed patent malaria. Protected subjects had higher levels of CS antibody titers on day of challenge than did nonprotected subjects. After immunization, 1 protected subject had increased cytotoxic T lymphocyte activity against CS and recall of memory T cell responses to RTS,S and selected CS.
- enzyme-linked immunosorbent assay
- amino acids
- hepatitis
- antigens
- surface antigens
- fluorescent antibody technique
- hepatitis b surface antigens
- immunization
- lipid a
- malaria
- malaria, falciparum
- plasmodium falciparum
- mental recall
- safety
- t-lymphocytes, cytotoxic
- vaccines
- yeasts
- antibodies
- patents
- memory t cells
- carboxyl group
- antibody titer
- sporozoites